Adage Capital Partners’s Regenxbio RGNX Stock Holding History

Adage Capital Partners’s Portfolio RGNX Stock Details RGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-500,000	Closed	-$3.87M	–	924
2024 Q4	$3.87M	Buy	+500,000	New	+$4.69M	0.01%	740
2024 Q2	–	Sell	-165,073	Closed	-$3.48M	–	931
2024 Q1	$3.48M	Buy	+165,073	New	+$2.94M	0.01%	736
2018 Q3	–	Sell	-300,000	Closed	-$21.5M	–	752
2018 Q2	$21.5M	Sell	300,000 -300,000	-50%	-$14.3M	0.05%	382
2018 Q1	$17.9M	Buy	600,000 +175,000	+41%	+$5.09M	0.04%	426
2017 Q4	$14.1M	Sell	425,000 -50,000	-11%	-$1.51M	0.03%	504
2017 Q3	$15.7M	Buy	475,000 +150,000	+46%	+$3.38M	0.04%	468
2017 Q2	$6.42M	Hold	325,000	–	–	0.02%	613
2017 Q1	$6.27M	Sell	325,000 -25,000	-7%	-$482K	0.02%	591
2016 Q4	$6.49M	Buy	350,000 +175,000	+100%	+$3.34M	0.02%	584
2016 Q3	$2.45M	Buy	175,000 +125,000	+250%	+$1.38M	0.01%	642
2016 Q2	$400K	Hold	50,000	–	–	﹤0.01%	671
2016 Q1	$540K	Hold	50,000	–	–	﹤0.01%	673
2015 Q4	$830K	Sell	50,000 -25,000	-33%	-$496K	﹤0.01%	666
2015 Q3	$1.65M	Buy	+75,000	New	+$1.91M	﹤0.01%	682

Other funds holding RGNX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Adage Capital Partners's RGNX Position: Q1 2025 in Review

Adage Capital Partners sold out of Regenxbio (RGNX) in Q1 2025, closing a stake of 500,000 shares — an estimated $3.87M sold.

Adage Capital Partners first reported a position in RGNX in Q3 2015 and held it in 14 quarters. The position peaked at $21.5M in Q2 2018. 164 funds tracked by Wall St. Rank hold RGNX as of Q1 2025.

Adage Capital Partners reported no remaining Regenxbio position as of Q1 2025 after selling out during the quarter.
Adage Capital Partners sold 500,000 Regenxbio shares in Q1 2025, an estimated $3.87M.
Adage Capital Partners first reported a position in Regenxbio in Q3 2015 and held it in 14 quarters.
Adage Capital Partners's Regenxbio position peaked at $21.5M in Q2 2018.
164 funds tracked by Wall St. Rank held Regenxbio as of Q1 2025.

Based on Adage Capital Partners's 13F filing for Q1 2025, filed 15 May 2025.